Among them, a few, one in 100,000 to 200,000 as the incidence developed to CTLN2 at adult age (10 to 80 years old) with symptoms including hyperammonemia, consciousness disturbance, and abnormal behavior. This evidence concerns the gene SLC25A13 and Hyperammonemia.